
## Carla Montironi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3091063/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature, 2021, 592, 450-456.	13.7	649
2	Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury. Journal of Hepatology, 2019, 70, 458-469.	1.8	173
3	Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. Journal of Hepatology, 2020, 73, 315-327.	1.8	164
4	Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology, 2018, 67, 1683-1694.	3.6	114
5	Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. Journal of Hepatology, 2021, 75, 865-878.	1.8	111
6	lmmunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma. Hepatology, 2021, 74, 2652-2669.	3.6	95
7	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut, 2023, 72, 129-140.	6.1	90
8	Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. British Journal of Cancer, 2019, 121, 340-343.	2.9	62
9	An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents. Gastroenterology, 2019, 157, 1383-1397.e11.	0.6	62
10	Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. British Journal of Cancer, 2017, 117, 1777-1786.	2.9	58
11	Liver CPT1A gene therapy reduces dietâ€induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD. FASEB Journal, 2020, 34, 11816-11837.	0.2	44
12	Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma. Clinical Cancer Research, 2022, 28, 2449-2460.	3.2	39
13	Validation of whole-slide imaging in the primary diagnosis of liver biopsies in a University Hospital. Digestive and Liver Disease, 2017, 49, 1240-1246.	0.4	24
14	New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma. Clinical Liver Disease, 2019, 14, 56-61.	1.0	23
15	Lymph node pooling: a feasible and efficient method of lymph node molecular staging in colorectal carcinoma. Journal of Translational Medicine, 2017, 15, 14.	1.8	19
16	Endoscopic tattooing of early colon carcinoma enhances detection of lymph nodes most prone to harbor tumor burden. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 723-733.	1.3	18
17	Hepatic epithelioid hemangioendothelioma: An international multicenter study. Digestive and Liver Disease, 2020, 52, 1041-1046.	0.4	13
18	Infiltrative xanthogranulomatous cholecystitis mimicking aggressive gallbladder carcinoma: A diagnostic and therapeutic dilemma. World Journal of Gastroenterology, 2017, 23, 8671-8678.	1.4	9

Carla Montironi

#	Article	IF	CITATIONS
19	Oropharyngeal Syphilis: Imaging and Pathologic Findings in Two Patients. Head and Neck Pathology, 2017, 11, 399-403.	1.3	7
20	Viral eradication and fibrosis resolution in post–liver transplant cholestatic hepatitis C virus. Liver Transplantation, 2018, 24, 703-707.	1.3	5
21	Spermidine Supplementation Protects the Liver Endothelium from Liver Damage in Mice. Nutrients, 2021, 13, 3700.	1.7	5
22	NeumonÃa organizada con desenlace fatal tras quimioterapia adyuvante con FOLFOX. Archivos De Bronconeumologia, 2015, 51, 610.	0.4	4
23	Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitits after liver transplantation. GastroenterologAa Y HepatologAa, 2020, 43, 14-21.	0.2	2
24	Organizing Pneumonia With Fatal Outcome After Adjuvant Chemotherapy with FOLFOX. Archivos De Bronconeumologia, 2015, 51, 610.	0.4	1
25	Targeted sequencing and molecular profiling of a papillary and cribriform clear cell intrahepatic cholangiocarcinoma reveals absence of selectable mutations. GastroenterologÃa Y HepatologÃa, 2019, 42, 374-375	0.2	0